Recent Updates — LUNG

Pulmonx Corporation reported third-quarter 2026 worldwide revenue of $22.8 million, a 6% increase from the prior year period. U.S. sales rose 7% to $14.9 million, while international revenue grew 5% to $7.9 million, excluding China where commercial activity is restarting. Gross margin improved to 76%, and operating expenses decreased 18% to $24.9 million due to cost realignment efforts. The company posted a net loss of $8.4 million, or $0.19 per share, compared to a $14.0 million loss in the same period last year, representing a 40% reduction. Adjusted EBITDA loss narrowed by 57% to $3.5 million. Cash and cash equivalents stood at $52.7 million as of September 30, 2026. Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD).

Pulmonx Corporation reported financial results for the second quarter ended June 30, 2026. Worldwide revenue decreased 5% to $22.8 million, driven by a lack of sales in China while international revenue excluding China grew 12%. The company achieved a record gross margin of 78%, and operating expenses fell 16% to $26.8 million due to cost realignment efforts. Net loss narrowed to $10.1 million ($0.24 per share) from $15.2 million in the prior year period, with adjusted EBITDA loss reducing by 39%. Cash and cash equivalents stood at $55.8 million as of June 30, 2026. The company maintained its full-year 2026 revenue guidance between $90 million and $92 million. Pulmonx Corporation operates in the medical device industry, developing minimally invasive treatments for chronic obstructive pulmonary disease (COPD).